ReviewMolecular diversity2026
Computational approaches for identifying quorum sensing inhibitors.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quorum sensing (QS) is a critical cell-to-cell communication mechanism employed by microorganisms to coordinate their collective behaviors, including biofilm formation, virulence regulation, and development of antimicrobial resistance (AMR). Disruption of QS using quorum sensing inhibitors (QSIs) has emerged as a promising anti-virulence strategy for combating multidrug-resistant bacterial infections. This review focuses on new technologies in drug discovery applied to the identification and optimization of QSIs, with particular emphasis on computational and data-driven methods. The key methodologies discussed include molecular docking, molecular dynamics simulations, virtual screening, and quantitative structure-activity relationship (QSAR) modeling. Studies demonstrating the successful application of these technologies against clinically relevant pathogens, such as Pseudomonas aeruginosa and Chromobacterium violaceum, are highlighted to illustrate the structure-guided QSI discovery. In addition, this review examines the current challenges in QSI development, including target specificity, resistance avoidance, and translational limitations. Recent advances in machine learning, artificial intelligence assisted screening, and systems biology-based modeling are also discussed as transformative tools that enhance hit identification, lead optimization, and mechanistic understanding. Collectively, these emerging technologies underscore the potential of QS-targeted drug discovery to deliver innovative anti-virulence therapies and contribute to global efforts to mitigate AMR.
Indexed as
Identifiers
42240764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.